A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is the first study of the safety of increasing dose levels of AEB1102 in patients with
Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will
also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid
levels and the antitumor effects of AEB1102.